This clinical trial is focused on studying a condition known as Gorlin Syndrome, which is a genetic disorder that can lead to the development of multiple skin cancers called Basal Cell Carcinomas (BCCs). The study is testing a treatment called Patidegib Gel 2%, which is applied directly to the skin. The purpose of the study is to evaluate how effective and safe this gel is in reducing the number of BCCs that develop on the face of adults with Gorlin Syndrome.

Participants in the study will be randomly assigned to use either the Patidegib Gel or a Vehicle Gel, which does not contain the active medication. The study will last for 12 months, during which participants will apply the gel twice daily to their face. Throughout the study, the number of new BCCs will be monitored, along with any changes in the size of existing BCCs and any side effects experienced by the participants.

The study aims to determine if Patidegib Gel can effectively reduce the burden of BCCs in individuals with Gorlin Syndrome, potentially offering a new way to manage this condition. Participants will be closely monitored by healthcare professionals to ensure their safety and to gather data on the gel’s effectiveness in preventing new BCCs from forming.